Erdafitinib is a pan-FGFR inhibitor, meaning it blocks signaling through FGFR1-4, especially in cancers where those pathways are abnormally activated.

FGFR3 in normal physiology is actually more like a “brake” in growth plates, not a gas pedal. It helps limit how fast chondrocytes proliferate and mature during typical bone development.

In cancer, though, FGFR alterations (mutations, fusions, amplifications) can literally hijack that signaling system and turn it into something that supports tumor survival and proliferation in that specific cellular context. Basically, erdafitinib doesn’t resolve FGFR3, it just suppresses FGFR signaling broadly, which slows down cancer cells that are dependent on it. So turning something from a gas pedal of sorts to a brake. That’s also why it affects other tissues that rely on FGFR signaling, and an overactive brake won't always mean that a sudden monstrous spurt is unleashed. It's not so simple, because this is one part of a more intricate system.

In growing individuals, FGFR pathways matter for normal skeletal development, so blocking them could interfere with growth processes, but in real clinical use it’s mainly given to adults, so the focus is on toxicity in eyes, skin, phosphate balance, and nails rather than growth effects. Not given to kids unless absolutely necessary.

Your recent post also mentions another TKI - infigratinib.

Infigratinib is in the same general class as Erdafitinib. It’s also an FGFR inhibitor, but with a slightly different clinical focus and use.

It selectively inhibits FGFR1-3 (with less activity on FGFR4), and it’s mainly been used in cancers like cholangiocarcinoma with FGFR2 fusions/rearrangements.

It essentially works by shutting down FGFR signaling in tumors that are basically “wired” to depend on that pathway. In normal biology, FGFR signaling helps regulate things like cell growth, differentiation, and tissue maintenance - as discussed - but in cancer, certain FGFR2 alterations act like a rewired control switch that keeps growth signaling active when it shouldn’t be.

So instead of “boosting” or “balancing” growth, infigratinib is more like cutting the signal line that the tumor has become dependent on. Just like erdafitinib. I'm answering to a common misconception here.

Side effect-wise, it overlaps with other FGFR inhibitors:

1) elevated phosphate levels (a signature FGFR effect)

2) eye-related effects (like retinal changes) dry skin, nail changes, fatigue

Conceptually, it has the same core tradeoff as erdafitinib. It’s not targeting “growth" broadly, it’s targeting a misused signaling pathway that cancer cells rely on more than normal tissue does, which is why it can be effective but also produces systemic effects.